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of urological organs, necessitating resection and reconstruction, which can be associated with
significant complications.
Methods: We retrospectively reviewed 20 patients undergoing urological reconstructions dur-
ing pelvic oncological surgeries from January 2004 to December 2013. All patients had imaging-
proven involvement of at least one urological organ preoperatively. Primary outcome was uro-
logical complication rate. Secondary outcomes were nonurological complication, recurrence
rate, and overall survival.
Results: Median age of presentation was 51 years. Six and 14 patients underwent resections for
primary and secondary tumors, respectively. Colorectal tumors were the most common, fol-
lowed by gynecological cancers. The ureter was the most common urological organ involved,
followed by the bladder, prostate, and seminal vesicles. Reconstructive procedures included
ileal and sigmoid conduits, ureteroneocystostomies, Boari flap, transureteroureterostomies
(TUUs) and direct ureteroureterostomies. Six patients developed major urological complica-
tions, requiring endoscopic and surgical reinterventions. The follow-up time was 34 months.
Thirteen patients developed recurrence, associated with higher tumor grade and lymphovas-
cular invasion, and occurred at a median time of 10 months. These patients had an overall sur-
vival of 20 months, compared to 45 months in patients without recurrence.
Conclusion: Careful patient selection in pelvic oncological surgeries can significantly prolong
survival. Recurrent tumors and greater intraoperative blood loss are associated with higher
urological complications. A limited pelvic exenteration and lower radiation doses can reduceConflicts of interest: All authors declare no conflicts of interest.
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+ MODELcomplication rates. If higher doses are necessary, conformal techniques and hyperfractionated
radiotherapy should be explored. Urological reconstruction should be individualized, according
to the extensiveness of urological involvement and exposure of radiation.
Copyright ª 2016, Asian Surgical Association. Published by Elsevier Taiwan LLC. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
In patients with locally advanced pelvic malignancy, there
is frequent involvement of the urological organs. In fact,
the urinary bladder is the second most commonly involved
(27%) and resected (24%) organ, after the small bowel, in
multivisceral resections for the treatment of locally
advanced colorectal cancer.1,2 In order to achieve clear
margins in pelvic oncological surgeries for primary or
recurrent pelvic tumors, urological organs are often
resected en bloc and reconstructed.3
Studies have shown that acceptable urological morbidity
can be achieved during complete resection of bulky primary
or recurrent pelvic tumors. Major urological complications
occur in 12e32%4e6 of cases. Of these, urinary fistulas and
obstruction have been identified as the most frequent and
potentially life threatening. Of note, a high postoperative
morbidity rate is often reported in patients with a history of
prior irradiation,5,6 which has been attributed to post-
radiation sclerosis and fibrosis of the urinary tract.7
Urological reconstruction has become an integral part of
pelvic exenterations and other radical pelvic oncological
surgeries. The choice of reconstruction is made after
careful consideration, and should ultimately optimize
quality of life without compromise on the completeness of
resection. The purpose of this study is to review our in-
stitution’s experience with patients who underwent uro-
logical reconstruction during pelvic oncological surgery,
specifically to assess the urological complications related to
the reconstruction.
2. Methods
The Singapore Health Services Centralized Institutional
Review Board approved the study. We retrospectively
reviewed patients who had undergone urological recon-
struction during pelvic oncological surgery from January
2004 to December 2013, at the Department of Surgical
Oncology, National Cancer Centre Singapore.
All patients underwent extensive preoperative staging
investigations, which included computed tomographic
scans of the chest, abdomen, pelvis or positron emission
tomogram computed tomographic scans to exclude meta-
static disease. Pelvic magnetic resonance imaging scans
were routinely performed to assess the radial involvement
and invasion to the pelvic sidewall, as well as the sacrum.
All patients had tumors extending and involving at least one
urological organ on preoperative imaging studies.
In patients whose surgery necessitated a total cys-
tectomy, transintestinal noncontinent urinary diversion was
performed using a 15 cm length of distal ileum, and ureter-
oenteric anastomoses were performed in a standardPlease cite this article in press as: Tan YG, et al., Urological reconstr
rience, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/j.spatulated Bricker anastomosis.8 In patients with minimal
ureteral defects, an ipsilateral end-to-end ureter-
oureterostomy was performed. Patients with a partial cys-
tectomy or a more significant involvement of the distal or
midureter were managed with a Boari flap reconstruction, a
transureteroureterostomy (TUU) or an end-to-side ureter-
oneocystostomy with or without a psoas hitch.
The primary outcome was overall urological complica-
tion rate. In particular, we limited major urological com-
plications to reconstruction-related complications, which
included leaks, fistulas, strictures, and hydronephrosis, for
consistency with other studies.4,8,9 Secondary outcomes
were nonurological complication, recurrence rate, and
overall survival.
3. Results
3.1. Patient profile
In our study timeline, 97 patients underwent pelvic onco-
logical surgery, which involved the resection of multiple
pelvic visceral organs. In particular, we focused on 20 pa-
tients who had preoperative imaging-proven urological
involvement and subsequently required urological recon-
struction at the time of surgery. There were 11 females and
nine males, with a median age of 51 years (range 24e76
years). Six patients (30%) underwent resection of the pri-
mary cancer, while the remaining 14 patients (70%) had
surgery for recurrent tumors. The median time to recur-
rence after primary resection was 30 months (13e70
months). Colorectal cancer was the primary tumor in 11
patients (55%), followed by gynecological malignancies in
six patients (30%). Other tumors include retroperitoneal
Ewing sarcoma, desmoid tumor and gastrointestinal stromal
tumor (Table 1).
A total of 13 patients (65%) had received previous
radiotherapy and 17 patients (85%) had undergone previous
chemotherapy.
3.2. Operative course
All 20 patients had tumor invasion of at least one urological
organ, with 10 of them (50%) having more than a single
organ invasion. The ureter was the most commonly involved
urological organ (nZ 17), followed by the bladder (nZ 12),
and the prostate and seminal vesicle (nZ 1).
Six patients (30%) had a total cystectomy and bilateral
distal ureterectomies, five patients (25%) underwent partial
cystectomy with unilateral distal ureterectomy, six patients
(30%) had resection of unilateral ureter, two patients had
bilateral ureterectomies, and one patient (5%) underwent
total cystectomy only. Frozen sections were sentuction after pelvic oncological surgery: A single institution expe-
asjsur.2016.02.002
Table 1 Reconstruction and complication rates.
Patient
no.
Primary/
recurrent
Malignancy Pre-op RT Involved
urological
organ
Reconstruction Major urological
complications
Management Minor
urological
complications
Major
nonurological
complications
Management
1 Recurrent Uterus Yes
(> 45 Gy)
Bladder,
ureter
Boari flap Bladder leak Laparotomy
washout and repair
of bladder leak
Sigmoid leak,
pelvic abscess
Laparotomy,
washout and
repair of leak
2 Primary Sigmoid No Bladder Ileal conduit e e UTI e e
3 Recurrent Sigmoid No Bladder,
ureter
Ureteroureterostomy e e Acute limb
ischemia with
compartment
syndrome
Left external
iliac
embolectomy,
fasciotomy
4 Primary Rectal Yes
(> 45 Gy)
Bladder,
prostate,
seminal
vesicle
Ileal conduit e e e e
5 Primary Rectal Yes
(> 45 Gy)
Bladder,
ureter
Ileal conduit Ileal conduit leak Laparotomy
washout and
bilateral end
ureterostomies
Pelvic abscess Laparotomy,
washout
6 Recurrent Cervix Yes Bladder,
ureter
Ileal conduit e e e e
7 Primary Rectal Yes Bladder,
ureter
Ileal conduit e e UTI e e
8 Primary Sigmoid Yes Ureter Boari flap e e Urinary
catheter leak
e e
9 Recurrent Ovary No Bladder,
ureter
Transureteroureterostomy Hydronephrosis DJ stent e e
10 Recurrent Retroperitoneal
Ewing sarcoma
Yes Ureter Ureteroneocystostomy e e Thrombosis of
obturator graft
Emergency
thrombectomy
11 Recurrent Desmoid tumor No Ureter Ureteroneocystostomy e e Pelvic abscess CT guided
drainage
12 Recurrent Colon Yes Ureter Boari flap e e e e
13 Recurrent Ovary No Bladder,
ureter
Ureteroureterostomy e e UTI Bilateral
pneumothoraces
Chest tubes
insertions
14 Recurrent Rectal Yes Ureter Ureteroneocystostomy Hydronephrosis DJ stent e e
15 Recurrent GIST No Ureter Ureteroneocystostomy Ureteric leak,
vesicocutaneous
and vesicorectal
fistulas
Temporary
occlusion of
bilateral ureters,
with PCN insertions
UTI e e
16 Recurrent Sigmoid Yes Ureter Ureteroneocystostomy e e e e
17 Recurrent Ovary No Ureter Transureteroureterostomy e e UTI e e
(continued on next page)
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Please cite this article in press as: Tan YG, et al., Urological reconstr
rience, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/j.intraoperatively and all patients achieved negative margins
on frozen section analysis and final histology.
The urological reconstructions performed were as fol-
lowed: six patients (30%) had an ileal conduit, five patients
(25%) had a ureteroneocystostomy, four patients (20%) had
a Boari flap, two patients (10%) had a TUU, two patients
(10%) had an ipsilateral ureteroureterostomy, and one (5%)
had a sigmoid conduit. A bladder hitch procedure was
performed on four patients, two of which were psoas
hitches, one was a sacral hitch, and the last was onto the
pelvic sidewall.
The median operating time was 465 minutes (380e700
minutes), with a median blood loss of 1350 mL
(500e9000 mL) and a median perioperative blood trans-
fusion of 975 mL (305e7200 mL). Table 1 summarizes the
patients’ surgical course.3.3. Postoperative course
All patients had a pelvic drain placed intraoperatively. At
the surgeon’s discretion, 12 patients with persistently high
drain output had their drain fluid tested for creatinine. Four
patients (33%) had grossly elevated creatinine levels
ranging from 1699 mmol/L to 2199 mmol/L.
A total of 18 patients had ureteric stents deployed intra-
operatively after urological reconstruction. Radiological in-
vestigations were routinely performed postoperatively to
detect any anastomotic leak. Twelve patients had their
stents removed after the investigations showed no anasto-
motic leak or stricture. Four patients had urinary leaks that
required stenting to maintain urinary diversion. Finally,
there were two patients with postoperative urinary stric-
tures that necessitate long-term ureteric stenting.
The median length of hospital stay was 20 days (7e99
days). There was no 30-day mortality in our study, but the
overall morbidity rate was 85% (nZ 17).
Urological complications were seen in 11 patients (55%),
among whom six (30%) had major complications. Four had
urinary anastomotic leaks, with one having concomitant
vesicocutaneous and rectovaginal fistulas. Three of these
patients required washout and revision of anastomoses and
another patient (Table 1: Patient number 18) had a ureteric
leak from Boari flap reconstruction that was managed
conservatively with an indwelling catheter on low inter-
mittent suction. The remaining two patients had progres-
sive hydronephrosis secondary to strictures, and were
managed with permanent ureteric stents.
The most common minor urological complication was
urinary tract infection (nZ 5), with positive urine culture
results, followed by one patient with urinary catheter leak.
Higher intraoperative blood loss was associated with
greater likelihood of major urological complications (Table
2). In this group of patients, the mean blood loss was more
than twice the volume compared to patients who did not
develop urological complications (3467 mL vs. 1543 mL,
pZ 0.047). Other factors associated with major urological
complications include the nature of tumor (primary vs.
recurrent) and preoperative hydronephrosis, although not
statistically significant. By contrast, age, gender, and
comorbidities did not affect the urological outcomes.uction after pelvic oncological surgery: A single institution expe-
asjsur.2016.02.002
Table 2 Factors affecting major urological complications.
Major
urological
complications
No major
urological
complication
p
Gender 0.624
Male 2 6
Female 4 8
Age (y) 0.574
 50 3 6
 50 3 8
Tumor 0.124
Primary 1 5
Recurrent 5 9
Preoperative
hydronephrosis
0.077
Yes 6 8
No 0 6
Previous radiation 0.634
Yes 4 9
No 2 5
Preoperative
chemotherapy
0.517
Yes 5 10
No 1 4
Mean operating
time (min)
490 498.6 0.913
Mean
intraoperative
blood loss (mL)
3466.7 1542.9 0.047
Charlson
comorbidity
index
5.33 6.93 0.625
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+ MODELOf the 13 patients who underwent radiation prior to
surgery, four (31%) developed anastomotic leaks or stric-
tures, compared to two of the seven patients (27%) in the
remaining group that did not receive preoperative radia-
tion. In particular, three of the four irradiated patients who
developed anastomotic urinary leaks received much higher
radiation dose, in excess of 45 Gy.
Two patients had worsening renal function post-
operatively, recorded at 1 and 12 months after surgery,
with estimated glomerular filtration rate (eGFR) of 48 mL/
min and 41 mL/min at the 12th month period. Continued
renal function monitoring at the 18th and 24th month in-
tervals for these patients remained stable. Both were likely
related to adjuvant chemotherapy induced nephropathy, as
repeat imaging ruled out any anatomical obstruction.
Nonurological complications were seen in 13 patients.
Seven patients suffered major complications, defined by
Clavien-Dindo classification of Grade 3 and above,10 of
which four occurred intraabdominally (Table 1). One pa-
tient had a small bowel perforation and required immedi-
ate open laparotomy with resection of the involved
segment of small bowel. Three patients had intraperitoneal
collections, of which two required relook laparotomies and
one was managed with percutaneous drainage. One patient
had an acutely ischemic limb; another had obturator graft
thrombosis while the last patient developed bilateralPlease cite this article in press as: Tan YG, et al., Urological reconstr
rience, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/j.apneumothoraxes from positive pressure ventilation. In all,
only two patients (10%) had concomitant major urological
and nonurological complications.
The median follow-up time was 34 months (6e124
months). Thirteen (65%) patients developed recurrences at
a median time of 10 months (range 2e32 months) and the
median overall survival for these patients was 20 months
(8e45months). Themedianoverall survival for the remaining
seven patients free of recurrence, at the time of last follow
up, was 45 months (range 24e124 months). Seven patients
had local recurrence in the pelvic region, and six had distant
metastases, namelypulmonary (3), bony (2), andhepatic (1).
In particular, within the colorectal cancer group that formed
the majority of patients, we noted early recurrences in both
the patients who had high grade tumors (2 and 7 months),
while in the remaining nine patients with moderately
differentiated cancer, only six patients had recurrences, at a
median time of 10.8 months (range 5e21 months). Also, the
presence of lymphovascular invasion in previous histology
was found to be a statistically significant prognostic factor
for recurrence. This was seen in seven of the eight patients
within the colorectal group (pZ 0.07).4. Discussion
Malignancies arising in the pelvis may be complicated by
invasion of urological organs, and often require urological
resection and reconstruction, in order to obtain surgically
negative margins and render a chance of cure.
In this series, although all the patients had a urological
organ invaded by pelvic cancer, a total pelvic exenteration
was performed in only six patients (30%). An exenteration is
avoided if a clear surgical margin can be obtained with a
less extensive procedure. Bladou et al5 and Houvenaeghel
et al6 have both documented significant major urological
complications associated with total pelvic exenterations,
which were attributed to a greater devascularization of
pelvic organs. Similarly, out of the 12 patients who had
bladder involvement, only seven patients had a total cys-
tectomy. The decision to retain the bladder must be
weighed against the most important goal of microscopically
negative margins.
Overall morbidity for such major surgeries remains high,
ranging between 38% and 65%.7,11,12 In particular, post-
operative associated major urological complications can
range from 12% to 32%.4e6 In a 10-year review done by
Memorial Sloan Kettering Cancer Centre (MSKCC) on 47
patients who underwent urinary diversion after total pelvic
exenterations for rectal cancer,4 there were a total of eight
major urological complications; two anastomotic leaks,
three urinary strictures, and three hydronephrosis.
In our study, six patients (30%) suffered from significant
urological complications of leaks, strictures, and hydro-
nephrosis. These may be due to a few factors. Firstly, the
majority of the patients were undergoing surgery for
recurrent tumors, and may have multiple previous surgical
attempts. The exenterative exercise becomes more
complicated with repeated resections and vascular
compromise of remaining organs after dissection may
compromise healing. Our results similarly showed that
surgeries involving recurrent tumors were associated withuction after pelvic oncological surgery: A single institution expe-
sjsur.2016.02.002
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+ MODELmore urological leaks (Table 2). More importantly, we also
demonstrated that a greater amount of intraoperative
blood loss can devascularize the pelvic organs and
compromise anastomoses, which accounted for the higher
urological complications.
Previous radiotherapy has long been recognized to
contribute to postoperative major surgical
complications.13e15 It is proposed that a process of pro-
gressive microvascular sclerosis and fibrosis occurs in irra-
diated tissues, increasing the complication rate of
anastomotic breakdowns.16 In our study, patients who were
previously irradiated have a higher rate of postoperative
major urological complications, albeit not statistically sig-
nificant (pZ 0.63). More importantly, we noted a stronger
correlation between higher radiation doses and urological
complications. Of the four irradiated patients who devel-
oped anastomotic urine leaks, three of them received
radiotherapy doses> 45 Gy. In contrast, only one of the nine
patients who received radiotherapy of < 45 Gy developed
strictures and none had urinoma. Our results concur with
larger studies that showed a dose dependent relationship
between radiation and urological complications.5,17,18
Therefore, in patients who may potentially require pel-
vic reconstructive surgery, it is important to balance the
benefit of pelvic radiotherapy with the risk of postoperative
urological complications. Usual doses for radiotherapy of
gastrointestinal and gynecological malignancies range from
45 Gy to 54 Gy.19,20 When disease features are favorable, it
is important to limit radiotherapy doses to  45 Gy. How-
ever, in the presence of adverse features such as T4 dis-
ease, threatened resection margins or heavy node
positivity, higher radiotherapy doses may be required.
Modern radiotherapy techniques such as intensity
modulated radiation therapy allow highly conformal doses
to be delivered to the target volume with preferential
sparing of the organs-at-risk,21,22 and can be used effec-
tively to reduce doses to critical organs. A proposed strat-
egy is to alter the radiotherapy fractionation so as to
preferentially spare the organs-at-risk while maintaining
the same desired dose to the tumor volume. Normal tissue
is generally more sensitive to large fraction sizes while
tumor cells tend to remain sensitive even at low doses.
Therefore, employing a hyperfractionated radiotherapy
schedule where lower doses per fraction are delivered
twice a day, i.e., 1.2 Gy bidaily, compared to a larger
fraction size once a day, i.e., 2 Gy daily, would allow
preferential sparing of normal tissue while allowing the
same tumoricidal dose to be delivered to the target vol-
ume. This strategy has been successfully employed in
reirradiation of pelvic malignancies23,24 and could poten-
tially be exploited in the setting where reconstructive
surgery is anticipated.
By contrast, for patients who have been exposed to high
dosages of radiation and are at significant risk of vascular
compromise, the method of urological reconstructions must
be tailored. We recommend the use of other nonirradiated
bowel segment as conduits. Bladou et al5 and Soper et al25
suggested transverse colon or jejunal conduits for tran-
sintestinal urinary diversion in patients who have received
previous high doses of pelvic radiotherapy. Ileum conduits
tend to have a higher fistulization rate given its relatively
limited tolerance to radiation.Please cite this article in press as: Tan YG, et al., Urological reconstr
rience, Asian Journal of Surgery (2016), http://dx.doi.org/10.1016/j.In cases where an irradiated bladder is too thickened for
an elongation procedure, a TUU has been shown to be a
good alternative,26 bypassing irradiated bladder areas
where vascularity is compromised and risked anastomotic
breakdowns. Noble et al27 showed excellent results of
> 97% success rate with no damage to the recipient ureter.
In our study, of the four patients who had prior pelvic
irradiation and subsequently underwent Boari flap recon-
struction, two had major urological complications that
required surgical reexploration. By contrast, only one of
the two patients with TUU developed hydronephrosis sec-
ondary to stricture of the contralateral distal ureter.
Although a long-term ureteric stent was required, this pa-
tient avoided surgical reexploration and there was no per-
manent impaired renal function after stenting.
Aggressive surgical management may be required for
urinary anastomotic leaks and fistulas. Conservative man-
agements are often ineffective with protracted recovery.10
In our study, of the four patients who presented with
anastomotic leak or urinary fistulas, three patients required
reoperations, after failing initial conservative manage-
ments. The remaining one patient had persistent anasto-
motic leak at the Boari flap that eventually sealed off after
6 weeks of indwelling catheter with low intermittent suc-
tion. Other larger studies of major urological complications
after pelvic surgeries have noted similar results.4,28 In a
study by Manuel et al28 of 66 patients who underwent uri-
nary diversion after gynecological surgeries, only one out of
the five urinary leaks was managed conservatively.
Undeniably, recurrence rate remained high, ranging from
38% to 65%.4,15 As such, we also evaluated the factors that
would suggest a poorer candidate for these extensive pelvic
surgeries. Patient demographics (age, gender, and comor-
bidity index) and nature of tumor (primary or recurrent) did
not prognosticate subsequent disease recurrence or overall
survival. The heterogeneity of tumor origins (colorectal,
gynecological, gastrointestinal stromal tumour (GIST),
Ewing’s and desmoid) added to the complexity of comparing
outcomes across different patients. However, focusing on
the colorectal patientswho form themajority of the patients
in our study, we noted several findings. The tumor grade and
lymphovascular invasion have direct correlations with sur-
vival, as consistent with larger studies.29,30 Both patients
who had high grade tumor, despite clear resection margins,
had recurrences, at 2 months and 7 months, respectively,
while in the remaining group with moderately differentiated
cancer, six out of nine had recurrences, at a median time of
10.8 months (range 5e21 months). Of the eight patients that
recurred, seven had lymphovascular invasion on final his-
tology. Dionne,29 in an analysis of 1376 rectal carcinomas,
observed that microscopic venous or lymphatic invasion was
associated with 47% incidence, of blood-borne metastases,
in stark comparison to 27% in the absence of invasion. We
postulated that patients with high aggressive tumor biology
may be less suitable for aggressive pelvic exenteration,
given the associated morbidity of such surgery and high
recurrence rate in these patients.
Ultimately, the decision to undertake such extensive
pelvic oncological surgeries should involve a multidisci-
plinary team, with consideration of the patient’s profile
and fitness, and the tumor biology and extensiveness.
These decisions were not the primary outcomes of thisuction after pelvic oncological surgery: A single institution expe-
asjsur.2016.02.002
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+ MODELstudy and should be further explored in parallel research
that exhibits greater homogeneity in selecting patients with
similar tumor profile for comparison of survival outcomes.
5. Conclusion
Extensive pelvic oncological surgeries involving urological
reconstruction often present with significant urological
complications. Patients with recurrent tumors and greater
intraoperative blood loss tend to have higher complication
rates, owing to greater devascularization and compromised
anastomoses. A limited pelvic exenteration and lower ra-
diation doses can reduce complication rates, but should be
weighed against the importance of good tumor control. If
higher doses are necessary, conformal techniques and
hyperfractionated radiotherapy should be explored. Uro-
logical reconstruction should be individualized, and con-
siderations include using nonirradiated bowel loops for
conduit reconstruction, and substituting direct elongation
procedures with TUU in irradiated urological organs.
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